Skip to main content
Signal8

VolitionRx Highlights a Transformational Year: Clinical Validation, Commercial Partnerships, and Potential Upcoming Milestones

$VNRXPress releaseNov 17, 2026, 9:31 AM ETRead the release

VolitionRx published a 2026 progress review citing >95% early-stage cancer detection in a blinded 81-subject Capture-Seq cohort and peer-reviewed validation of Nu.Q® NETs for predicting sepsis mortality. Revenue grew 134% year-to-date to $3.0 million, while operating costs fell 13% and convertible note debt was cut by over $5.0 million to roughly $0.7 million.

Key figures

Revenue
3000000
Revenue Yoy
134%
Patents
over 70
Licensing discussions
more than a dozen diagnostic companies
Detecseps program value
€6.3 million (~$7.3 million)
Feline lymphoma detection
86% at 97% specificity
Ytd operating cost change
-13%
Ytd operating loss change
-24%
Potential feline milestone
$5 million
Capture seq sensitivity stage1
94%
Capture seq sensitivity stage2
96%
Capture seq overall sensitivity
93% at 95% specificity
Convertible note debt reduction
$5.0 million
Remaining convertible note principal
~$0.7 million

AI analysis

Red flags3 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    VNRX: VolitionRx Highlights a Transformational Year: Clinical Validation, Commercial Partnerships, and Potential Upcoming Milestones — AI Analysis | Signal8